The Herbert Irving Comprehensive Cancer Center participates in a wide range of innovative, feasibility or proof of principle trials originating from its research programs and initiated by institutional Pis. Enrollment in these studies has been maintained throughout the last grant period. The conduct of these studies is supported by research nursing and data management provided by the Clinical Research Management Office (CRMO). Research Nursing focuses solely on the eligibility, consenting and management of patients on clinical trials. In addition to its participation in the scope of high-priority clinical trials, Herbert Irving Comprehensive Cancer Center has conducted a series of innovative phase I trials of cancer vaccines and immunotherapy that have provided important information on the mechanisms and clinical efficacy of these agents. There is an increasing emphasis on interaction between basic science and clinical research as exemplified by ongoing translational studies in breast cancer and lymphoma. Expanded support for our participation in high priority and innovative trials is requested. The projected operating budget for Protocol Specific Research Support is $352,247, of which we are requesting 100% support from the CCSG.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA013696-39S3
Application #
8637172
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-07-04
Project End
2014-06-30
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
39
Fiscal Year
2013
Total Cost
$136,392
Indirect Cost
$51,147
Name
Columbia University (N.Y.)
Department
Type
DUNS #
621889815
City
New York
State
NY
Country
United States
Zip Code
10032
Bassuk, Alexander G; Sujirakul, Tharikarn; Tsang, Stephen H et al. (2014) A novel RPGR mutation masquerading as Stargardt disease. Br J Ophthalmol 98:709-11
Li, Yao; Wu, Wen-Hsuan; Hsu, Chun-Wei et al. (2014) Gene therapy in patient-specific stem cell lines and a preclinical model of retinitis pigmentosa with membrane frizzled-related protein defects. Mol Ther 22:1688-97
Wert, Katherine J; Sancho-Pelluz, Javier; Tsang, Stephen H (2014) Mid-stage intervention achieves similar efficacy as conventional early-stage treatment using gene therapy in a pre-clinical model of retinitis pigmentosa. Hum Mol Genet 23:514-23
Shen, Sherry; Sujirakul, Tharikarn; Tsang, Stephen H (2014) Next-generation sequencing revealed a novel mutation in the gene encoding the beta subunit of rod phosphodiesterase. Ophthalmic Genet 35:142-50
Palomero, Teresa; Couronné, Lucile; Khiabanian, Hossein et al. (2014) Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nat Genet 46:166-70
Higuchi-Sanabria, Ryo; Pernice, Wolfgang M A; Vevea, Jason D et al. (2014) Role of asymmetric cell division in lifespan control in Saccharomyces cerevisiae. FEMS Yeast Res 14:1133-46
Lam, A T; Curschellas, C; Krovvidi, D et al. (2014) Controlling self-assembly of microtubule spools via kinesin motor density. Soft Matter 10:8731-6
Olszak, Torsten; Neves, Joana F; Dowds, C Marie et al. (2014) Protective mucosal immunity mediated by epithelial CD1d and IL-10. Nature 509:497-502
Murtomaki, Aino; Uh, Minji K; Kitajewski, Chris et al. (2014) Notch signaling functions in lymphatic valve formation. Development 141:2446-51
Nong, Eva; Lee, Winston; Merriam, Joanna E et al. (2014) Disease progression in autosomal dominant cone-rod dystrophy caused by a novel mutation (D100G) in the GUCA1A gene. Doc Ophthalmol 128:59-67

Showing the most recent 10 out of 142 publications